ProFound
Powered by iCAD

Creating a world where
Cancer Can't Hide.

ProFound AI®
Breast Health Suite

Breast cancer has finally met its match.

iCAD

Quality healthcare, reimagined.

Together, we can change more lives.

Backed by science, clinical evidence, and proven patient outcomes, our suite of artificial intelligence (AI) solutions shine a spotlight on cancer, exposing its hiding place. Empowering you to personalize breast cancer screening like never before.

ProFound offers unrivaled accuracy, as well as multi-vendor compatibility and unique workflow advantages.

ProFound Breast Health Suite

- Cancer **Detection**[1]
- **Density** Assessment[1]
- **Risk** Evaluation[2]
- **Heart** Health[3]

Real World Clinical Results

23% relative increase in cancer detection rate without increasing the rate of recalls.[8]

8M+ annual mammograms read

A partner you can count on.

US Based Organization
Headquarters: Nashua, NH

Diverse US Based Algorithm
100+ contributing facilities

FDA Cleared: ProFound AI
First DBT AI Cleared in December 2018

Applied AI Healthcare Challenge
2023 Award Winner – Cancer (ProFound AI)

Experience the ProFound AI difference.

Cancer Detection

Concurrent-read detection solution for 2D and 3D mammography that rapidly detects malignant soft tissue densities and calcifications with unrivaled accuracy and industry-leading AUC performance.

2x Performance compared to other AI platforms.[5]

8% Improvement in sensitivity.[4]

7% Reduction in recall rate.[4]

52% Reduction in reading time.[4]

Find or predict cancers 2-3 years earlier.[6,7]

Density Assessment

High Breast Density Rating

**Consider Supplemental Screening**[9] (e.g. ABUS / MRI)

Standardization matters.
Provide an objective and consistent BI-RADS breast density assessment, seamlessly integrated into existing workflows.

Unique two-part algorithm assesses the **dispersion** and localized **concentration** of breast density.

Risk Evaluation

1st Image-based, one- or two-year risk assessment tool. Identifies high risk of developing breast based only on a 2D or 3D mammogram.[2]

2.4x More accurate compared to traditional lifetime models.[6,7]

Risk Model Performance

80% AUC performance.
Offering similar results in women with dense and non-dense breasts.

ProFound
Powered by ✦ iCAD

Meet the
ProFound Scorecard.

Automated, integrated, and easy to read. The ProFound Scorecard provides an actionable mammographic case summary.

Provides the information needed to personalize patient care.

Critical Insights at a Glance.

- Color-coded Overall Case Score.

- Automated Density Assessment Score.

- Personalized 1-2 year Risk Score.[2]

- Worklist Prioritization by Case Scores.*

Patient Name: ewbth0000556
Patient ID: ewbth0000556
Patient DOB/Age: 078Y
Accession #:
Study Date: 7/27/2018 2:21:40 PM

ProFound Breast Health Suite
ProFound AI® Scorecard

ProFound AI Detection Case Score

62

0   19   69   100

62
C+

PowerLook Density Assessment

3.8

| a | b | c | d |
1.0   2.0   3.0   4.0

H 0.65%

ProFound AI Risk: DBT
Absolute Risk 1-Year

0.65%

| General | Moderate | High |
0.0%   0.34%   0.6%

Average Risk at Age 78: 0.43%

*Worklist and color based on PACS viewer and output requirements.

Flexible turnkey deployment.

ProFound Cloud

ProFound On-Premises

Visit iCADmed.com to request a demo

1. FDA Cleared. CE Marked. Health Canada Licensed. 2. ProFound Risk is CE marked (MDD) and Health Canada Licensed. May not be available in all geographies. 3. Heart Health may not be available in all geographies. 4. Conant EF, et al. Radiology: Artificial Intelligence 2019. 5. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm. Accessed 1-20-23. FDA 510K submissions K182373 (iCAD), K201019 (Hologic) and K193229 (ScreenPoint). 6. Mikael Eriksson et al. A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care. Sci. Transl. Med. 14, eabn3971 (2022). DOI: 10.1126/scitranslmed.abn3971. 7. Eriksson M, Czene K, Strand F, Zackrisson S, Lindholm P, Lång K, Förnvik D, Sartor H, Mavaddat N, Easton D, Hall P. Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening. Radiology. 2020 Nov;297(2):327-333. doi: 10.1148/radiol.2020201620. Epub 2020 Sep 8. PMID: 32897160. 8. Schilling, K. Presented Research at ECR 2023; Vienna, Austria. 9. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. J Am Coll Radiol. 2023 Sep;20(9):902-914. doi: 10.1016/j.jacr.2023.04.002. Epub 2023 May 5. PMID: 37150275

Disclaimer: Images may vary based on regulatory clearance and/or configuration.

✦ iCAD

www.icadmed.com
1.866.280.2239